887625-09-4

Basic information

• Product Name: 2-Amino-6-chloroimidazo[1,2-b]pyridazine
• Synonyms: 2-Amino-6-chloroimidazo[1,2-b]pyridazine;6-Chloroimidazo[1,2-b]pyridazin-2-amine;6-Chloroimidazo[2,1-f]pyridazin-2-amine
• CAS NO: 887625-09-4
• Molecular Formula: C₆H₅ClN₄
• Molecular Weight: 168.5837
• Mol File: 887625-09-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Density: 1.71
• Refractive Index: 1.791
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.03±0.30(Predicted)
• CAS DataBase Reference: 2-Amino-6-chloroimidazo[1,2-b]pyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-6-chloroimidazo[1,2-b]pyridazine(887625-09-4)
• EPA Substance Registry System: 2-Amino-6-chloroimidazo[1,2-b]pyridazine(887625-09-4)

Safety Data

• Hazardous Substances Data: 887625-09-4(Hazardous Substances Data)

Usage

General Description

2-Amino-6-chloroimidazo[1,2-b]pyridazine is a chemical compound with the molecular formula C7H6ClN5. It is a heterocyclic aromatic compound that contains an imidazo[1,2-b]pyridazine ring system with a chlorine atom in the 6-position and an amino group in the 2-position. 2-Amino-6-chloroimidazo[1,2-b]pyridazine is of interest in the pharmaceutical industry due to its potential as a building block in the synthesis of biologically active compounds. It has been studied for its potential as an anti-cancer agent and is also being investigated for its antimicrobial properties. Additionally, 2-Amino-6-chloroimidazo[1,2-b]pyridazine has been used in research as a precursor for the synthesis of various nitrogen-containing heterocycles.

InChI:InChI=1/C6H5ClN4/c7-4-1-2-6-9-5(8)3-11(6)10-4/h1-3H,8H2

Upstream product

• 1244059-53-7 (Z)-2-(3-chloro-6-(tosylimino)pyridazin-1(6H)-yl)acetamide 
• 947248-50-2 N-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-2,2,2-trifluoroacetamide 
• 1162680-83-2 azido(6-chloroimidazo[1,2-b]pyridazin-2-yl)methanone 

Downstream Products

• 1005776-70-4 N-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-4-(tert-butyl)benzamide 

Relevant articles and documents

Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity

RIPK1 plays a key role in the necroptosis pathway that regulates inflammatory signaling and cell death in various diseases, including inflammatory and neurodegenerative diseases. Herein, we report a series of potent RIPK1 inhibitors, represented by compound 70. Compound 70 efficiently blocks necroptosis induced by TNFα in both human and mouse cells (EC50 = 17–30 nM). Biophysical assay demonstrates that compound 70 potently binds to RIPK1 (Kd = 9.2 nM), but not RIPK3 (Kd > 10,000 nM). Importantly, compound 70 exhibits greatly improved metabolic stability in human and rat liver microsomes compared to compound 6 (PK68), a RIPK1 inhibitor reported in our previous work. In addition, compound 70 displays high permeability in Caco-2 cells and excellent in vitro safety profiles in hERG and CYP assays. Moreover, pre-treatment of 70 significantly ameliorates hypothermia and lethal shock in SIRS mice model. Lastly, compound 70 possesses favorable pharmacokinetic parameters with moderate clearance and good oral bioavailability in SD rat. Taken together, our work supports 70 as a potent RIPK1 inhibitor and highlights its potential as a prototypical lead for further development in necroptosis-associated inflammatory disorders.

AMINOIMIDAZOPYRIDINES AS KINASE INHIBITORS

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Inhibitors of PI3 kinase

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, that inhibit phosphoinositide 3-kinase; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds.